March 2010
Strengthening Solid-state Capabilities

Syntagon is strengthening its solid-state capabilities with the appointment of Associate Professor Sitaram Velaga as a scientific adviser. A recognized expert in the field of co-crystal and polymorphism of APIs, Professor Velaga has published more than 20 papers and is a frequent speaker on the topic.

 

Co-crystallization is a technique that manipulates clinically relevant characteristics of an API such as solubility, dissolution, stability and bioavailability by crystallizing it with a carrier or co-crystal former. Common coformers have GRAS (generally regarded as safe) status and include carbohydrates such as saccharin.

 

"We are delighted to be working with Sitaram; his extensive skills and experience will allow us to expand our services in the field of solid-state development," says Syntagon CEO Michael Lofthagen.

 

"I'm immensely excited by this opportunity: my expertise in solid state research further strengthens Syntagon's existing skills," Sitaram adds.

 

 

 

March 2010
Isolation of saponins from Quillaja extract by preparative HPLC

In the latest in our series of technical articles providing insights of our work, we describe how Swedish adjuvant manufacturer and research organization, Isconova, and Syntagon are collaborating.

Isconova's adjuvant technology is based on the Immune Stimulating Complex (ISCOM) technology platform, where the key constituents are saponins. These are isolated from Quillaja extract by preparative reversed phase liquid chromatography. Originally this was done manually and was considered inefficient and expensive. Low reproducibility and online monitoring meant batches were discarded.

 

In this article Syntagon describes how, together with Isconova, a new method for preparative chromatography was developed with a focus on efficiency, quality, cost reduction, automation and reproducibility by optimizing the following variables:

 

• Chromatographic parameters
• Loading capacity
• Scale-up
  

Download full article as PDF

 

 

 

March 2010
Syntagon Teams with Xcelience

In an exciting new strategic partnership between Syntagon and US-based formulation company Xcelience, Syntagon is to represent Xcelience's business development interests in Scandinavia.

 

Xcelience is the leading powder into capsule (PIC) service provider, enabling clients to fill very small amounts of active pharmaceutical ingredients (API) directly into capsules, thus reducing time to first-in-human (FIH) studies.

 

"I'm convinced that this collaboration will be beneficial to our customers by giving them swift access to a trusted and reliable formulation development partner," says Syntagon CEO Michael Lofthagen.

 

"Syntagon is uniquely positioned in the Scandinavian market and like us, they are experts in their field. By working together we hope to provide customers with a faster and more cost-effective way of launching early phase clinical trials," adds Xcelience CEO Derek Hennecke.